Global Partners L.P. (GLP)
NYSE NYSE Primary 
Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent
The $63-billion GLP-1 agonist industry is forecast to triple in the coming decade, so it's no surprise that pharmaceuticals companies of all sizes are scrambling to get in on the action. For the time being, though, the market is still dominated by two names: Eli Lilly and Co. NYSE: LLY and Novo Nordisk A/S NYSE: NVO.
Eli Lilly crushes Q1 estimates, raises full-year outlook as GLP-1 sales surge
Eli Lilly and Co (NYSE:LLY) reported stronger-than-expected first-quarter 2026 results on April 30, driven by surging demand for its diabetes and obesity treatments Mounjaro and Zepbound. Shares rose about 8% following the release.
Should Value Investors Buy Global Partners (GLP) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance Means
GLP-1 seller Hims & Hers Health NYSE: HIMS has seen significant volatility in its stock price as of late. Notably, despite seeing a 41% single-day surge in early March, HIMS remains down nearly 10% in 2026.
Eli Lilly Is More Than GLP-1 Drugs. The Stock Looks Attractive.
The acquisition of Kelonia Therapeutics, announced this week, is part of Lilly's expansion into cancer treatments.
Ceasefire extension, Best Buy's new CEO, Amazon's GLP-1 push and more in Morning Squawk
Here are five key things investors need to know to start the trading day.
Amazon.com to Offer Program for GLP-1 Weight-Loss Drugs
Amazon One Medical members can get Novo Nordisk's Wegovy and Eli Lilly's Foundayo GLP-1 pills in a program that integrates primary-care services with the technology company's pharmacy business.
Amazon shakes GLP-1 race as Eli Lilly, Novo Nordisk stocks fall
Amazon is expanding its footprint in healthcare, unveiling a new program aimed at simplifying access to weight-loss treatments and reshaping how GLP-1 drugs are delivered to patients. The move positions the tech giant as a growing force in the obesity drug market, long dominated by pharmaceutical leaders Eli Lilly and Novo Nordisk.
Health insurers raise questions about Medicare program that will offer GLP-1s to seniors for $50
Some health insurers are pushing back against a new program that will allow Medicare beneficiaries to pay $50 per month for GLP-1 medications for weight loss.
Amazon launches GLP-1 weight loss program, promising 'fast, convenient' access
Amazon One Medical launched a GLP-1 program integrating obesity care with Amazon Pharmacy. Pricing for the popular weight loss drugs will begin at as low as $25 per month with insurance.
3 Ways to Invest in the Growing GLP-1 Weight Loss Market
Weight loss drugs are big business, with the GLP-1 receptor agonist market expected to nearly triple in size to $185 billion by 2033, a compound annual growth rate of about 12.4%. Although increasingly a global medical phenomenon, the bulk of the market still exists in the United States, and domestic investors can get in on the action by targeting companies that manufacture these powerful drugs.
Hims & Hers Health Stock Rallies on Regulatory Pivot. It's Not About GLP-1s This Time.
Hims has signaled its interest in peptides, many of which have been banned for use in compounding pharmacies.
